Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 13/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.34 |
| ▸ | F3 | P13726 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8362598 | 0.90 | F7 (0.41) | F7MAPKAPK2SYKEGLN2AURKA | |
| SCHEMBL6791806 | 0.90 | F7 (0.40) | F7SYKEGLN2 | |
| SCHEMBL6792414 | 0.89 | F7 (0.41) | F7EGLN2AURKARPS6KB1 | |
| SCHEMBL8360889 | 0.87 | F7 (0.39) | F7SYKEGLN2AURKARPS6KB1 | |
| SCHEMBL8363696 | 0.86 | F7 (0.38) | F7SYKEGLN2AURKARPS6KB1 | |
| SCHEMBL6792938 | 0.86 | F7 (0.38) | F7F3 | |
| SCHEMBL6792932 | 0.86 | F7 (0.38) | F7F3 | |
| SCHEMBL8360318 | 0.86 | F7 (0.38) | F7SYKEGLN2AURKARPS6KB1 | |
| SCHEMBL8362513 | 0.85 | F7 (0.37) | F7DGAT1 | |
| SCHEMBL6792372 | 0.85 | F7 (0.38) | F7SYKEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | F7 20/4885MAPKAPK2 2536/4885F3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.